MONTREAL, March 11, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-US) specialty pharmaceutical company, announced today that it has entered into a ...

MONTREAL, March 11, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-US) specialty pharmaceutical company, announced today that it has entered into a ...

MONTREAL, June 17, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today that it has completed the ...

MONTREAL, March 11, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-US) specialty pharmaceutical company, announced today ...

MONTREAL, March 11, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American ... Knight Therapeutics To Acquire Paladin. Date. 2025-03-11 06:46:00.

Knight Therapeutics Inc: Knight Therapeutics closes Paladin acquisition: 17.06. Knight Therapeutics Inc: Knight secures $50M (U.S.) revolving credit facility: 17.06. Stocks in Play: Knight ...

Detailed price information for Knight Therapeutics Inc (GUD-T) from The Globe and Mail including charting and trades.

Knight Therapeutics Inc. (TSX:GUD) offers investors exposure to the lucrative specialty pharmaceutical market.

In 2024, Paladin generated revenues of $70 million excluding products that Paladin has stopped commercializing or is in the process of discontinuing. "The reunion of Paladin and Knight, two companies ...